Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) declared its 64th consecutive annual dividend increase on April 14, 2026, lifting its quarterly payout from $1.30 per share to $1.34 per share, a…
Joel South Warren Buffett built his fortune by buying businesses with durable competitive advantages at reasonable prices and holding them for decades. Now well into the second half of 2026, four ETFs stand out…
It can be an interesting proposition to replace your salary with dividend stocks. However, it isn’t as easy as it sounds. Replacing a salary of $85,000 in retirement through dividend stocks needs…
Pre-Market Stock Futures: The futures are exploding higher, as, fortunately, President Trump chose not to “end civilization in Iran” and agreed to a two-week pause on attacks on Iran. In contrast, Iran…
AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204. JPMorgan isn’t running from that weakness — it’s calling it a buying opportunity,…
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Coca-Cola (NYSE:KO) both closed out 2025 with Q4 earnings and have raised dividends for 63 consecutive years. But beneath that shared milestone sit…
It can be an appealing idea to replace your paycheck with passive income. While it sounds exciting on the surface, it is a slightly complicated task. You'll have to work backwards and…
With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for Boomer and Gen X retirees. Without some degree of growth, portfolios built…
Markets have delivered plenty of twists lately, with inflation cooling but growth uneven and volatility still lurking around every earnings corner. Smart investors know one truth holds steady: reliable income beats hype…
Rich Duprey The VIX has climbed 41% in a single month, sitting at 26.95 and in the 93rd percentile of the past year’s readings. For retirement investors who felt last April’s volatility spike to…
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline. Right now, that diversification is being…
Retirees and income-focused investors have long used Vanguard Value ETF (NYSEARCA:VTV) as a core portfolio anchor, drawn to its dividend income, lower volatility relative to growth funds, and near-zero cost structure. When…
Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT), a pure-play sector fund that has quietly compounded wealth for long-term investors…
A 1.5% yield sounds unimpressive until you realize the dividend check doubles roughly every seven years. That is the premise behind the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG): skip the high-yield traps and…
Half of every dollar invested in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) rides on just two companies pulling in opposite directions in 2026. With a 0.38% expense ratio, nearly $1.1 billion in net…
